ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

182.74
-6.52
(-3.44%)
Closed September 18 4:00PM
184.00
1.26
(0.69%)
After Hours: 7:59PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
184.00
Bid
182.20
Ask
291.38
Volume
335,082
182.185 Day's Range 190.835
93.95 52 Week Range 219.34
Market Cap
Previous Close
189.26
Open
190.02
Last Trade Time
Financial Volume
$ 62,300,828
VWAP
185.9271
Average Volume (3m)
274,633
Shares Outstanding
28,729,950
Dividend Yield
-
PE Ratio
480.13
Earnings Per Share (EPS)
0.38
Revenue
50.7M
Net Profit
10.93M

About Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $189.26. Over the last year, Krystal Biotech shares have traded in a share price range of $ 93.95 to $ 219.34.

Krystal Biotech currently has 28,729,950 shares outstanding. The market capitalization of Krystal Biotech is $5.44 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 480.13.

Krystal Biotech (KRYS) Options Flow Summary

Overall Flow

Bullish

Net Premium

34k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

KRYS Latest News

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...

Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study...

U.S. Index Futures and Oil Prices Plunge on Recession Concerns

U.S. index futures fell sharply after a volatile week, with the Nasdaq Composite entering correction territory due to recession concerns and uncertainties about Federal Reserve actions. At 04:37...

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.34-0.722995575699185.34203.285182.69388376194.80359732CS
4-15.46-7.75092750426199.46206.97181.36223192194.73177479CS
123.742.07478087207180.26219.34166.905274633193.34016186CS
2612.397.21985898258171.61219.34144.0001325738179.19468331CS
5264.4753.9362503137119.53219.3493.95339058152.04502843CS
156126.05217.51509922357.95219.3438.8563272976110.96067817CS
260139.1309.79955456644.9219.3431.8922214595.61606853CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OMEXOdyssey Marine Exploration Inc
$ 1.39
(180.07%)
328.97M
PRTGPortage Biotech Inc
$ 9.7581
(115.41%)
51.55M
APLTApplied Therapeutics Inc
$ 7.86
(69.03%)
51.67M
XCHXCHG Ltd
$ 18.40
(65.77%)
1.26M
WBUYWeBuy Global Ltd
$ 0.1867
(60.95%)
248.03M
GLMDGalmed Pharmaceuticals Ltd
$ 6.83
(-54.77%)
6.24M
KAKineta Inc
$ 0.5691
(-31.35%)
530.74k
DTSSDatasea Inc
$ 2.07
(-29.59%)
1.34M
CBUSCibus Inc
$ 3.595
(-28.95%)
2.31M
BFIBurgerFi International Inc
$ 0.1705
(-26.98%)
16.56M
OMEXOdyssey Marine Exploration Inc
$ 1.39
(180.07%)
324.51M
NVDANVIDIA Corporation
$ 113.37
(-1.92%)
304.66M
WBUYWeBuy Global Ltd
$ 0.18675
(60.99%)
228.66M
SQQQProShares UltraPro Short QQQ
$ 8.40
(1.45%)
197.87M
LUNRIntuitive Machines Inc
$ 7.47
(38.33%)
130.99M

KRYS Discussion

View Posts
Monksdream Monksdream 2 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 4 months ago
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 5 months ago
KRYS over $30
👍️0
Monksdream Monksdream 6 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 1 year ago
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 years ago
Moving nicely today...
👍️0
wiredawg wiredawg 3 years ago
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 years ago
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 years ago
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 years ago
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 years ago
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 years ago
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 years ago
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 years ago
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 years ago
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 years ago
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 years ago
3rd post
👍️0
crudeoil24 crudeoil24 3 years ago
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 years ago
..
👍️0

Your Recent History

Delayed Upgrade Clock